Clinical Trial Update: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of psilocybin therapy for depression and anxiety in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder
• Parkinson Disease

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Joshua Woolley, MD, PhD | Conditions: Parkinson Disease, Depression | Phase 2 | Status: COMPLETED